Table 1 Patient characteristics at baseline (n = 24)

male, n (%)

9 (38)

4 (31)

5 (45)

0.68^†

age (years), mean (SD) (range)

57.5 (13.4) (20–75)

56.7 (15.8) (20–75)

58.4 (10.6) (38–72)

0.91^‡

disease duration, (years), mean (SD) (range)

21.3 (12.5) (4–54)

21.2 (14.2) (4–54)

21.5 (10.7) (8–36)

0.68^‡

body mass index (kg/m²), mean (SD)

23.4 (4.8)

24.6 (5.1)

21.9 (4.1)

0.19^‡

smoking (never/former), n

18 / 6

9 / 4

9 / 2

0.65^†

 —ICS/LABA, n (%)

24 (100)

13 (100)

11 (100)

–

 —ICS dose (μg), mean (SD), budesonide equivalent

1381 (448)

1411 (518)

1345 (370)

0.66^‡

 —LAMA, n (%)

14 (58)

7 (54)

7 (64)

0.70^†

 —LTRA, n (%)

20 (83)

11 (85)

9 (82)

> 0.99^†

 —xanthine derivative, n (%)

17 (71)

9 (69)

8 (73)

> 0.99^†

 —maintenance therapy of OCS, n (%)

8 (33)

6 (46)

2 (18)

0.21^†

 —daily dose of OCS^a (mg), mean (range)

5.6 (1.0–15)

6.1 (1.0–15)

4.3 (2.5–6)

0.74^‡

 —ECRS, n (%)

20 (83)

10 (77)

10 (91)

0.60^†

 —EOM, n (%)

11 (46)

3 (23)

8 (73)

0.038^†

 —AERD, n (%)

7 (29)

6 (46)

1 (10)

0.08^†

 —EGPA, n (%)

4 (17)

1 (8)

3 (27)^b

0.30^†

 —atopic dermatitis, n (%)

1 (4)

1 (8)

0 (0)

> 0.99^†

 —omalizumab, n (%) / median (range) (month)

5 (21) / 11 (3–88)

1 (8) / 3 (3)

4 (40) / 15.5 (4–88)

0.14^† / 0.16^‡

 —mepolizumab, n (%) / median (range) (month)

11 (46) / 21 (5–35)

–

11 (100) / 21 (5–35)

–

 —dupilumab, n (%) / median (range) (month)

1 (4) / 6 (6)

1 (8) / 6 (6)

–

–

number of benralizumab injections, median (range)

8 (2–11)

8 (2–10)

7 (4–11)

0.98^‡

observation period (months), median (range)

11.5 (4–17)

11 (4–16)

14 (4–17)

0.79^‡